Position of the Transparency Council – Keytruda (pembrolizumab)
At its meeting on 27 January 2025, the Transparency Council adopted position No. 12/2025 on the evaluation of the drug Keytruda (pembrolizumab) within the B.141.FM drug program “Treatment of patients with urothelial carcinoma (ICD- 10: C61, C65, C66, C67, C68)”